doi: 10.1161/hs0901.94259
(Stroke. 2001;32:2143.)
© 2001 American Heart Association, Inc.
Original Contributions |
Protective Effect of Endothelin Type A Receptor Antagonist on Brain Edema and Injury After Transient Middle Cerebral Artery Occlusion in Rats
From the Discovery Research Laboratories, Shionogi and Co, Ltd, Toyonaka, Osaka, Japan.
Correspondence to Yoshiyuki Matsuo, PhD, Discovery Research Laboratories, Shionogi and Co, Ltd, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan. E-mail yoshiyuki.matsuo{at}shionogi.co.jp
Background and Purpose—— Recent evidence strongly suggests that endothelins (ETs) play an important role in the regulation of blood-brain barrier (BBB) functions. The aim of the present study was to evaluate the role of ETs on edema formation and BBB permeability change after cerebral ischemia/reperfusion.
Methods—— We examined the brain tissue ET-1 content and evaluated the time and dose response of the therapeutic effects of the specific ET type A receptor (ETA) antagonist, S-0139, on brain edema formation, development of infarction, and disruption of BBB after 1 hour of middle cerebral artery occlusion (MCAO) in rats.
Results—— After 1-hour MCAO and reperfusion, the brain ET-1 content did not change during the first 3 hours, increased at 6 hours, and rose almost continuously over 48 hours in the ischemic region as well as in the ischemic rim. Rats infused with S-0139 (0.03 to 1.0 mg/kg per hour) during reperfusion showed dose-dependent and significant attenuation of the increase in brain water content 24 hours after reperfusion. When the infusion of S-0139 was begun after 10 minutes and 1 hour of reperfusion, the brain edema formation and infarct size were significantly attenuated. Furthermore, posttreatment with S-0139 significantly attenuated the increased Evans blue dye-quantified albumin extravasation and improved the mortality of animals after cerebral ischemia/reperfusion.
Conclusions>—— Our data demonstrate that infusion with S-0139, an ETA antagonist, results in significant reduction of brain injury and plasma extravasation after transient MCAO. Thus, ETs may contribute to cerebral ischemia/reperfusion injury at least partly by increasing the BBB permeability via ETAs.
Key Words: blood-brain barrier • brain edema • brain injuries • cerebral ischemia, focal • endothelins • rats
This article has been cited by other articles:
 |
|
 |
|
  M. Austinat, S. Braeuninger, J. B. Pesquero, M. Brede, M. Bader, G. Stoll, T. Renne, and C. Kleinschnitz Blockade of Bradykinin Receptor B1 but Not Bradykinin Receptor B2 Provides Protection From Cerebral Infarction and Brain Edema * Expanded Materials and Methods Stroke, January 1, 2009; 40(1): 285 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Zhang, C. Zhang, L. Zhang, C. Roberts, M. Lu, A. Kapke, Y. Cui, M. Ninomiya, T. Nagafuji, B. Albala, et al. Synergistic Effect of an Endothelin Type A Receptor Antagonist, S-0139, With rtPA on the Neuroprotection After Embolic Stroke Stroke, October 1, 2008; 39(10): 2830 - 2836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Moldes, T. Sobrino, M. Millan, M. Castellanos, N. Perez de la Ossa, R. Leira, J. Serena, J. Vivancos, A. Davalos, and J. Castillo High Serum Levels of Endothelin-1 Predict Severe Cerebral Edema in Patients With Acute Ischemic Stroke Treated With t-PA Stroke, July 1, 2008; 39(7): 2006 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Liu, S. Mori, H. K. Takahashi, Y. Tomono, H. Wake, T. Kanke, Y. Sato, N. Hiraga, N. Adachi, T. Yoshino, et al. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats FASEB J, December 1, 2007; 21(14): 3904 - 3916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shimamura, G. Matchett, H. Yatsushige, J. W. Calvert, H. Ohkuma, and J. Zhang Inhibition of Integrin {alpha}v{beta}3 Ameliorates Focal Cerebral Ischemic Damage in the Rat Middle Cerebral Artery Occlusion Model Stroke, July 1, 2006; 37(7): 1902 - 1909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Battistini, N. Berthiaume, N. F. Kelland, D. J. Webb, and D. E. Kohan Profile of Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The Novel "-Sentan" Class of Drug. Experimental Biology and Medicine, June 1, 2006; 231(6): 653 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. S. Machado, M. S. Desruisseaux, Nagajyothi, R. P. Kennan, H. P. Hetherington, M. Wittner, L. M. Weiss, S. C. Lee, P. E. Scherer, M. Tsuji, et al. Endothelin in a murine model of cerebral malaria. Experimental Biology and Medicine, June 1, 2006; 231(6): 1176 - 1181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Andresen, N. I. Shafi, and R. M. Bryan Jr. Endothelial influences on cerebrovascular tone J Appl Physiol, January 1, 2006; 100(1): 318 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Fagan, D. C. Hess, E. J. Hohnadel, D. M. Pollock, and A. Ergul Targets for Vascular Protection After Acute Ischemic Stroke Stroke, September 1, 2004; 35(9): 2220 - 2225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shimamura, N. Sato, K. Oshima, M. Aoki, H. Kurinami, S. Waguri, Y. Uchiyama, T. Ogihara, Y. Kaneda, and R. Morishita Novel Therapeutic Strategy to Treat Brain Ischemia: Overexpression of Hepatocyte Growth Factor Gene Reduced Ischemic Injury Without Cerebral Edema in Rat Model Circulation, January 27, 2004; 109(3): 424 - 431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shuaib, C. Xu Wang, T. Yang, and R. Noor Effects of Nonpeptide V1 Vasopressin Receptor Antagonist SR-49059 on Infarction Volume and Recovery of Function in a Focal Embolic Stroke Model Stroke, December 1, 2002; 33(12): 3033 - 3037. [Abstract] [Full Text] [PDF]
|
|